Agammaglobulinemia

This is a condition where the body doesn't make enough antibodies, which are proteins that help fight infections. It means there are very few or no gamma globulins in the blood. This makes people more likely to get infections, especially from bacteria.

Condition

What people with Agammaglobulinemia report

Every report comes from a Lived member, sent anonymously.

Have you tried IVIG for Agammaglobulinemia?

NameHow it went

About Agammaglobulinemia

What It Is

Agammaglobulinemia is a rare inherited immune disorder in which the body makes very few or no antibodies. Antibodies (also called immunoglobulins) are proteins that latch onto bacteria and viruses, help the immune system destroy them and protect against catching some infections twice. They are made by B cells, a type of white blood cell. In agammaglobulinemia, B cells fail to mature in the bone marrow, so almost none reach the blood and antibody levels are extremely low. The result is repeated and sometimes serious infections, most often of the ears, sinuses, lungs and eyes, along with infections that cause ongoing diarrhea. Without treatment, these infections can spread into the bloodstream, bones, joints or brain. Babies are usually well for their first months because they are protected by antibodies passed from their mother before birth; infections typically begin somewhere between a few months and about a year and a half of age. The name is sometimes used loosely alongside hypogammaglobulinemia, which simply means low antibody levels. That broader term includes other immune disorders in which B cells are present but do not work well, and low levels caused by certain medicines or illnesses. Agammaglobulinemia is the specific, lifelong form in which B cells are essentially missing.

Causes & Risk Factors

Agammaglobulinemia is caused by a change (variant) in one of the genes B cells need in order to develop. It is present from birth and is not caused by anything a parent or child did. About 85% of cases are X-linked agammaglobulinemia (XLA), also called Bruton's agammaglobulinemia, caused by variants in the BTK gene on the X chromosome. This gene makes Bruton tyrosine kinase (BTK), a protein developing B cells need in order to mature. Because boys have only one X chromosome, XLA occurs almost entirely in males. Mothers and sisters can carry the variant without having symptoms, and each son of a carrier has a 50% chance of being affected. About half of boys with XLA have no family history, because the variant arose new in them. The remaining cases come from variants in several other genes involved in B cell development. These forms are usually autosomal recessive, meaning a child inherits one altered copy from each parent, so girls and boys are affected equally. The illness looks very much like XLA. Genetic testing tells families which form they have, which matters for counseling relatives and planning future pregnancies.

How It's Diagnosed

Agammaglobulinemia is considered in anyone, male or female, with repeated or unusually severe bacterial infections, especially when the tonsils and lymph nodes are very small or hard to find. Those tissues are largely made of B cells, so they stay small when B cells are absent. The first test is a blood measurement of immunoglobulins (IgG, IgM and IgA). In agammaglobulinemia, all of them are very low or absent. Interpreting results in young babies takes care, because healthy infants make only small amounts in the first months of life. The key next test counts B cells in the blood. A B cell level of about 1% of lymphocytes or less is the most reliable sign of agammaglobulinemia, and it separates the condition from other antibody deficiencies in which B cells are present. Genetic testing then confirms the cause, such as a BTK variant in XLA, and allows carrier testing for female relatives. A newborn whose brother, maternal uncle or maternal cousin has agammaglobulinemia should have B cells checked soon after birth, so treatment can begin before the first serious infection.

Treatment Options

There is currently no cure in routine use, but treatment works well at preventing the serious infections that otherwise define this condition. The core treatment is immunoglobulin replacement therapy: regular infusions of antibodies purified from the donated plasma of thousands of healthy people. These borrowed antibodies protect the body but are used up over time, and they do not teach the immune system to make its own. Treatment is therefore lifelong and must stay on schedule. Stopping or delaying it can quickly lead to severe pneumonia or bloodstream infection. Immunoglobulin can be given into a vein (intravenous immunoglobulin, or IVIG), usually every 3 to 4 weeks in a clinic or at home with a nurse, with each infusion taking a few hours. It can also be given under the skin (subcutaneous immunoglobulin, or SCIG), most often weekly and usually at home after training. Both routes prevent infections effectively. IVIG means fewer sessions but can bring a dip in protection before the next dose and more body-wide reactions, such as headache, chills, nausea or muscle aches during or after an infusion. SCIG gives steadier levels and fewer of those reactions, but more frequent sessions and some swelling or redness at the injection sites. The dose is adjusted by blood levels just before the next dose and, above all, by how often infections occur. Some people also take a daily antibiotic to prevent infections or to manage chronic sinus or chest problems, and infections that do occur are usually treated promptly and sometimes for longer than usual. Vaccines need specific planning. People with agammaglobulinemia should not receive live vaccines, such as measles-mumps-rubella (MMR), chickenpox, rotavirus, live oral polio or yellow fever, because these can rarely cause the very disease they are meant to prevent. A yearly flu shot is recommended, and household members should keep up with their own vaccines to reduce exposure.

What to Expect

With regular immunoglobulin replacement, most people with agammaglobulinemia lead active, relatively normal lives. Children can attend school, play team sports and take part in ordinary activities, and many adults work, travel and raise families. Infections still happen and may need quicker attention than in other people, but they should become much less frequent and less severe. Treatment shapes the routine. Infusions every few weeks or home injections every week become a fixed part of life, as do regular visits with an immunologist (a specialist in immune disorders), blood tests to check antibody levels and insurance approvals for an expensive, ongoing therapy. Many people find a route and schedule that fits school or work, and switching between IVIG and SCIG is possible if one suits better. The main long-term concern is the lungs. Repeated chest infections, particularly before diagnosis or when treatment is interrupted, can cause bronchiectasis, a permanent widening and scarring of the airways that leads to ongoing cough and mucus. People who develop it tend to have a noticeably lower quality of life, which is why early diagnosis, steady treatment and periodic lung checks matter. A smaller number of people develop other problems, such as a rare form of arthritis, autoimmune conditions or low levels of other white blood cells. Two practical points are worth knowing. Standard antibody blood tests for infections such as hepatitis are unreliable during immunoglobulin treatment, so clinicians need to use other kinds of tests. And because donated antibodies reflect what donors have encountered, they may protect poorly against newly circulating flu or COVID-19 strains.

When to Seek Help

Ask about an immune evaluation for a child or adult who has frequent ear, sinus or chest infections, infections that keep returning despite antibiotics or a serious infection such as pneumonia that needs hospital care, especially with a known family history. Family members of someone with agammaglobulinemia should ask about carrier testing or newborn testing. For someone already diagnosed, contact the care team promptly about a fever or new signs of infection, such as a cough, ear pain, red eyes or diarrhea that does not settle, because infections can progress faster without antibodies. Also call if infusions are missed or cannot be arranged, or if a severe headache after IVIG does not improve with over-the-counter pain relief. Seek emergency care for signs that an infection may have spread to the blood or brain: confusion or unusual drowsiness, a severe headache with a stiff neck, fast breathing or shortness of breath, or fever with cold, clammy skin and a feeling of being very unwell. Tell emergency staff about the diagnosis, since it changes how infections are treated.

Questions to Ask Your Doctor

  1. 1.Which form of agammaglobulinemia do I or does my child have, and what does that mean for other family members?
  2. 2.Would IVIG or SCIG fit better with our schedule and health, and how will we know the dose is right?
  3. 3.What should we do when a fever or infection starts, and when should we call you rather than wait?
  4. 4.Which vaccines are safe for me, and which should my household get to help protect me?
  5. 5.How will you check my lungs and watch for bronchiectasis or other long-term complications?

Last reviewed • Oct 2026

Educational content, not medical advice.